{
  "pmcid": "1876947",
  "pmid": "17522506",
  "title": "A Randomized, Controlled Trial of Postoperative Adjuvant Interferon Therapy After Resection of Hepatocellular Carcinoma",
  "abstract": "Objective:: We conducted a randomized controlled trial of adjuvant interferon therapy in patients with predominantly hepatitis B-related hepatocellular carcinoma (HCC) to investigate whether the prognosis after hepatic resection could be improved.\n\nSummary Background Data:: Recurrence is common after hepatic resection for HCC. Interferon possesses antiviral, immunomodulatory, antiproliferative, and antiangiogenic effects and may be an effective form of adjuvant therapy.\n\nPatients and Methods:: Since February 1999, patients with no residual disease after hepatic resection for HCC were randomly assigned with stratification by pTNM stage to receive no treatment (control group), interferon alpha-2b 10 MIU/m 2 (IFN-I group) or 30 MIU/m 2 (IFN-II group) thrice weekly for 16 weeks. Enrollment to the IFN-II group was terminated from January 2000 because adverse effects resulted in treatment discontinuation in the first 6 patients. By June 2002, 40 patients each had been enrolled into the control group and IFN-I group. The baseline clinical, laboratory, and tumor characteristics of both groups were comparable.\n\nResults:: The 1- and 5-year survival rates were 85% and 61%, respectively, for the control group and 97% and 79%, respectively, for the IFN-I group ( P = 0.137). After adjusting for the confounding prognostic factors in a Cox model, the relative risk of death for interferon treatment was 0.42 (95% CI, 0.17â€“1.05; P = 0.063). Exploratory subset analysis showed that adjuvant interferon had no survival benefit for pTNM stage I/II tumor (5-year survival 90% in both groups; P = 0.917) but prevented early recurrence and improved the 5-year survival of patients with stage III/IVA tumor from 24% to 68% ( P = 0.038).\n\nConclusion:: In a group of patients with predominantly hepatitis B-related HCC, adjuvant interferon therapy showed a trend for survival benefit, primarily in those with pTNM stage III/IVA tumors. Further larger randomized trials stratified for stage are needed.",
  "authors": [
    "Chung Mau Lo",
    "Chi Leung Liu",
    "See Ching Chan",
    "Chi Ming Lam",
    "Ronnie T. P. Poon",
    "Irene O. L. Ng",
    "Sheung Tat Fan",
    "John Wong"
  ],
  "journal": "Annals of Surgery",
  "year": "2007",
  "full_text": "",
  "pdf_url": "",
  "pdf_downloaded": false,
  "pdf_embedded_viewer": false
}